Recently, EH-P002A, a novel wound-healing drug developed by Exploring Health, LLC. has been proven to exert significant effects in promoting cellular migration and wound healing in both in vitro and in vivo experiments. The relevant research findings have been published in the journal Biochem Biophys Rep (Biochem Biophys Rep. 2026 Feb 4;45:102476. doi: 10.1016/j.bbrep.2026.102476).

Studies have demonstrated that EH-P002A shows no obvious cytotoxicity on HFF-1 fibroblasts and Beas-2B bronchial epithelial cells, and can accelerate wound healing in a dose-dependent manner in mouse models. More notably, the research team discovered the phenomenon of "cyto-impedance" for the first time through this drug: the drug can effectively promote cellular migration at low concentrations, while at high concentrations, it inhibits cellular migratory ability despite the absence of cytotoxicity.

The proposal of this brand-new concept reveals the potential dual characteristics of wound-healing promoting drugs. The study has also initially identified the gene expression signatures associated with this phenomenon, which provides an important basis for optimizing subsequent dosage regimens and avoiding cyto-impedance, and offers significant guiding significance for drug research and development in fields such as chronic wound treatment.